Characterization of renal angiotensin - Converting enzyme 2 in diabetic nephropathy

Hypertension

Volumn 41, Issue 3 I, 2003, Pages 392-397

  Tikellis, Christos ^a,b   Johnston, Colin I ^b   Forbes, Josephine M ^a,b   Burns, Wendy C ^a,b   Burrell, Louise M ^a   Risvanis, John ^a   Cooper, Mark E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Angiotensin; Angiotensin converting enzyme; Diabetes mellitus; Diabetic nephropathy

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; RAMIPRIL; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA SEQUENCE; DRUG EFFECT; ENZYME ANALYSIS; ENZYME LOCALIZATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY TUBULE; MALE; MEASUREMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARBOXYPEPTIDASES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY; KIDNEY TUBULES; MALE; PEPTIDYL-DIPEPTIDASE A; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 0037341501     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000060689.38912.CB     Document Type: Article

References (28)

1. Erdos EG. Conversion of angiotensin I to angiotensin II. Am J Med. 1976;60:749-759.
2. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
3. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 275:33238-33243.
4. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843.
5. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol. 1993;265:F477-F486.
6. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms [review]. Am J Kidney Dis. 1997;29:153-163.
7. Johnston CI, Fabris B, Jandeleit K. Intrarenal renin-angiotensin system in renal physiology and pathophysiology. Kidney Int Suppl. 1993;42:S59-S63.
8. Arima S, Ito S. New insights into actions of the renin-angiotensin system in the kidney: concentrating on the Ang II receptors and the newly described Ang-(1-7) and its receptor. Semin Nephrol. 2001;21:535-543.
9. Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG, Burns KD. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int. 2000;58:2320-2330.
10. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD. Early streptozotocin-diabetes mellitus downregulates rat kidney AT(2) receptors. Am J Physiol. Renal Fluid Electrolyte Physiol. 2001;280:F254-F265.
11. Zatz R, Dunn BR, Meyer TW, Brenner B. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
12. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen L, Jerums G, Cooper ME. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes. 1998;47:414-422.
13. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989;36: 526-536.
14. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
15. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 1991;40:1328-1334.
16. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G. Glomerular filtration rate in the streptozocin diabetic rat: the role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes. 1990;38:1182-1190.
17. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. Role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes. 1997;46:1612-1618.
18. Johnston H, Koukoulas I, Jeyaseelan K, Armugam A, Earnest L, Baird R, Dawson N, Ferraro T, Wintour EM. Ontogeny of aquaporins 1 and 3 in ovine placenta and fetal membranes. Placenta.. 2000;21:88-99.
19. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia. 2001;44:874-877.
20. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 2002;106:246-253.
21. Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
22. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.
23. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI, Cooper ME. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy: implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol. 1999;155:429-440.
24. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, Erdos EG. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension. 2002;39:976-981.
25. Erdos EG, Skidgel RA. Renal metabolism of angiotensin I and II. Kidney Int Suppl. 1990;30:S24-S27.
26. Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens. 1998;11:137-146.
27. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int. 2000;57:1882-1894.
28. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of lovartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.